XBP1 and melanoma: LINC02202 may further regulate immune infiltration and the efficacy of immune checkpoint treatments by modulating the miR‐526b‐3p/XBP1 signalling pathway, contributing to immune evasion, proliferation and metastasis of malignant melanoma.